October 23, 2021

Ultivue and Fluidigm Corporation announce agreement offering customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development.

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a […]
November 19, 2020

Ultivue and Indivumed partner for research and drug development in personalized oncology

HAMBURG, GERMANY and CAMBRIDGE, MA, USA – Ultivue and Indivumed today announced that the two companies have entered into a collaborative partnership to further accelerate research […]
August 10, 2020

Ultivue and OracleBio partner to help advance personalized tumor characterization and clinical oncology research using multiplex immunofluorescence

CAMBRIDGE, MA - Ultivue, Inc. today announced a collaborative partnership with OracleBio to help further insights and advance personalized tumor characterization in translational and clinical oncology research and drug development using multiplex immunofluorescence staining and imaging.
December 27, 2019

Olympus and Ultivue Announce Comarketing Agreement for Leading-Edge Fluorescent Multiplexing Solution

WALTHAM, Mass., (December 18, 2019)—Olympus, a premier manufacturer of life science imaging systems and Ultivue, a leading developer of tissue biomarker identification and quantification assays for translational research, have entered into a comarketing agreement. The partnership will provide a comprehensive solution to the scientific community’s increasing need for fluorescent multiplexing.
December 27, 2019

Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services

Kassel, Germany and Cambridge, MA, USA November 7, 2019 – Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays, to offer the biopharmaceutical industry new capabilities to improve the characterization of cancer patients’ samples selected for clinical research programs.
December 27, 2019

Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis

CAMBRIDGE, Mass – March 29, 2019. Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens, a pioneer […]
December 27, 2019

Ultivue to release a breakthrough 9-Color multiplex IHC panel achieving same day sample-to-analysis at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018

CAMBRIDGE, Mass, November 7, 2018 – Ultivue, a life science company developing reagent-driven strategies for high-performance biological imaging in situ, today announced expanded capabilities of its […]
Contact Us